|
Overview
Cells, tissues, and organs function in a 3-D environment. Ideally, cell-based models that capture both the 3-D organization and multicellular complexity of the target system provide the most powerful tools for screening the effects of therapeutic candidates. This meeting bridges tissue engineers who are constructing the 3-D models with biologists who are studying healthy vs. diseased states and pharmacologists who are developing high throughput screening assays. As with 3-D biological models, each specialty provides insight into the complete system. CHI's 2nd Annual Tissue Models for Therapeutics is a pharmaceutical conference where the attendees you meet are as important as the faculty
| Dr. Mina J. Bissell, Lawrence Berkeley National Laboratory
|
|
|
|
Dr. Sheng Ding, Genomics Institute of the Novartis Research Foundation |
|
|
|
Scientific Advisors
Dr. Angela Cacace, Bristol-Myers Squibb Co.
Dr. Jonathan Garlick, Tufts University
Dr. Linda Griffith, Massachusetts Institute of Technology
Dr. Robert Langer, Massachusetts Institute of Technology
|
Distinguished Faculty
Dr. Angela Cacace, Bristol-Myers Squibb Co.
Dr. Robin Felder, University of Virginia
Dr. Richard Fernandes, Luxcel Biosciences
Dr. Jonathan Garlick, Tufts University
Dr. Linda Griffith, Massachusetts Institute of Technology
Dr. Simon Goldbard, VitraBioscience
Dr. John Hambor, Pfizer Global Research and Development
Dr. John D. McNeish, Pfizer Global Research and Development
Dr. Norman Maitland, Pro-Cure Therapeutics
Dr. Cheryl Nickerson, Tulane University Health Sciences Center
Dr. Ivan Plavec, BioSeek, Inc.
Dr. Amy Sinor, Curis
Dr. Wilfred Stein, National Institutes of Health
Dr. Tetsuro Wakatsuki, InvivoSciences LLC
Dr. Mary Zacour, MDS Pharma Services
Ms. Nastaran Zahir, University of Pennsylvania
Dr. Robert R. Macek, Roche Diagnostics GmbH
For
sponsorship/exhibit information, please contact:
Carol Dinerstein, Manager of
Business Development
Phone: 781-972-5471 • E-mail: dinerstein@healthtech.com
|
